We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.45%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$620M
AUM Growth
-$22.5M
(-3.5%)
Cap. Flow
-$102M
Cap. Flow
% of AUM
-16.42%
Top 10 Holdings %
Top 10 Hldgs %
56.57%
Holding
63
New
7
Increased
6
Reduced
34
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XENT
Intersect ENT, Inc
XENT
|
+$8.69M |
| 2 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$5.06M |
| 3 |
Veracyte
VCYT
|
+$3.37M |
| 4 |
Invesco S&P SmallCap Health Care ETF
PSCH
|
+$2.38M |
| 5 |
CLLS
Cellectis
CLLS
|
+$2.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$57.3M |
| 2 |
NeoGenomics
NEO
|
+$20.2M |
| 3 |
AtriCure
ATRC
|
+$13M |
| 4 |
Ligand Pharmaceuticals
LGND
|
+$11.9M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$9.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.6% |
| 2 | Communication Services | 3.41% |
| 3 | Energy | 0.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NeoGenomics
NEO
$1.96B
| $56.8M | 9.17% |
3,700,927
-1,461,136
| -28% | -$20.2M |
|
2
Omnicell
OMCL
$1.61B
| $47.7M | 7.69% |
663,109
-3,000
| -0.5% | -$189K |
|
|
SHPG
3
DELISTED
Shire pic
SHPG
| $41.4M | 6.69% |
228,645
-1,076
| -0.5% | -$186K |
|
|
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
| $36.2M | 5.84% |
2,381,146
-10,429
| -0.4% | -$160K |
|
|
5
AtriCure
ATRC
$1.92B
| $34M | 5.48% |
969,193
-411,212
| -30% | -$13M |
|
6
Harvard Bioscience
HBIO
$27.5M
| $32.9M | 5.31% |
627,012
+31,911
| +5% | +$1.79M |
|
7
Heron Therapeutics
HRTX
$93.9M
| $26.4M | 4.25% |
833,001
-3,736
| -0.4% | -$139K |
|
|
OXFD
8
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $25.9M | 4.17% |
1,594,009
+353,618
| +29% | +$5.06M |
|
9
Ionis Pharmaceuticals
IONS
$8.6B
| $25.4M | 4.1% |
492,140
-2,207
| -0.4% | -$104K |
|
|
IMMU
10
DELISTED
Immunomedics Inc
IMMU
| $24M | 3.87% |
1,151,622
-5,876
| -0.5% | -$139K |
|
11
Nektar Therapeutics
NKTR
$2.39B
| $22.7M | 3.66% |
24,837
-113
| -0.5% | -$96.5K |
|
|
MODN
12
DELISTED
MODEL N, INC.
MODN
| $21.2M | 3.41% |
1,334,599
-5,323
| -0.4% | -$93.2K |
|
|
13
Ligand Pharmaceuticals
LGND
$5.76B
| $20M | 3.23% |
117,051
-79,257
| -40% | -$11.9M |
|
|
CSII
14
DELISTED
Cardiovascular Systems, Inc.
CSII
| $19M | 3.06% |
484,454
-2,753
| -0.6% | -$102K |
|
15
Xencor
XNCR
$1.5B
| $18.2M | 2.94% |
467,653
-94,154
| -17% | -$3.84M |
|
16
Halozyme
HALO
$9.79B
| $16.1M | 2.6% |
885,523
-4,206
| -0.5% | -$73.7K |
|
|
XENT
17
DELISTED
Intersect ENT, Inc
XENT
| $14.9M | 2.4% |
517,121
+289,238
| +127% | +$8.69M |
|
18
Codexis
CDXS
$151M
| $14.4M | 2.32% |
837,548
-3,871
| -0.5% | -$62.5K |
|
|
19
Veracyte
VCYT
$3.7B
| $11.3M | 1.83% |
1,187,694
+305,711
| +35% | +$3.37M |
|
|
20
Tandem Diabetes Care
TNDM
$1.34B
| $11.3M | 1.82% |
263,883
-1,640,377
| -86% | -$57.3M |
|
|
NVTR
21
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $8.42M | 1.36% |
382,908
-337
| -0.1% | -$6.48K |
|
|
KTWO
22
DELISTED
K2M Group Holdings, Inc
KTWO
| $7.93M | 1.28% |
289,756
-2,387
| -0.8% | -$55.9K |
|
|
DVAX
23
DELISTED
Dynavax Technologies
DVAX
| $6.77M | 1.09% |
546,265
-2,512
| -0.5% | -$34K |
|
24
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.04M | 0.97% |
62,298
-452
| -0.7% | -$45.1K |
|
25
Globus Medical
GMED
$10.7B
| $5.9M | 0.95% |
103,908
-707
| -0.7% | -$37.2K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q3 2018 Portfolio in Review
As of Q3 2018, First Light Asset Management held 63 positions worth $620M, down 3.5% from $642M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
First Light Asset Management withdrew a net $102M in Q3 2018, closing 4 positions and reducing 34 holdings. Its most notable exit was NEVRO CORP., an estimated $9.28M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Communication Services and Energy.
Against the trend, First Light Asset Management opened a new position in Invesco S&P SmallCap Health Care ETF worth $2.43M.
- First Light Asset Management's largest Q3 2018 buy was Invesco S&P SmallCap Health Care ETF: 51,855 shares worth $2.43M.
- First Light Asset Management added most to Intersect ENT, Inc in Q3 2018, an estimated $8.69M increase.
- First Light Asset Management's biggest Q3 2018 reduction was Tandem Diabetes Care, cutting an estimated $57.3M.
- First Light Asset Management fully exited NEVRO CORP. in Q3 2018, selling an estimated $9.28M.
- First Light Asset Management's ten largest holdings make up 57% of its $620M portfolio in Q3 2018.
- First Light Asset Management opened 7 new positions and closed 4 in Q3 2018.
- First Light Asset Management's portfolio value fell 3.5% quarter-over-quarter to $620M.
Based on First Light Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.